Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation: Nearly two decades of experience

Annals of the New York Academy of Sciences

Volumn 850, Issue , 1998, Pages 469-470

  Calleja, E M ^a   Shen, J Y ^a   Lesser, M ^b   Grady, R W ^a   New, M I ^a   Giardina, P J ^a,c  

^a Department of Obstetrics Gynecology   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFEROXAMINE; HEMOGLOBIN;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; HUMAN; HYPOTHYROIDISM; IRON OVERLOAD; MAJOR CLINICAL STUDY; MORBIDITY; PUBERTY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; THALASSEMIA MAJOR;

EID: 0031876334     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb10524.x     Document Type: Article

References (1)

1. GIARDINA, P. J., R. W. GRADY, K. H. EHLERS, et al. Current therapy of Cooley's anemia: A decade of experience with subcutaneous desferrioxamine. Ann. N.Y. Acad. Sci. 612: 275-285.